"Maximizing Shareholder Value Through Enhancing Corporate Value"
[Asia Economy Reporter Myung-hwan Lee] SK Biopharm announced on the 6th that President Lee Dong-hoon purchased 3,000 shares of the company's stock during his first week in office. The average acquisition price was 71,000 KRW per share, with a total acquisition amount reaching approximately 210 million KRW.
SK Biopharm explained that President Lee's purchase of company shares in his first week demonstrates his strong will and confidence to achieve the company's growth through responsible management, both internally and externally. They added that this act personally embodies the philosophy of maximizing shareholder value by enhancing corporate value.
Earlier, at the New Year's meeting on the 2nd, President Lee stated that he would accelerate innovation for the growth of the organization and its members this year. He pledged to elevate SK Biopharm into the only differentiated global healthcare company in Korea by maximizing sales of the innovative epilepsy drug cenobamate, securing next-generation pipelines, and strengthening communication with employees.
On the 6th (local time), President Lee plans to meet with Rene Ryan, President of SK Biopharm's digital therapeutics partner, Kala Health, at CES 2023, the world's largest electronics and IT exhibition held in Las Vegas, USA, to discuss ways to enhance future cooperation. He will then participate in the 2023 JP Morgan Healthcare Conference held in San Francisco from the 9th to the 12th, where he plans to meet with global companies and investors.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
